Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) is advancing research into myelin protection as a new focus for treating multiple sclerosis (MS), a chronic autoimmune disease affecting the central nervous system. The company is developing Lucid-MS, a drug candidate designed to address a key aspect of MS that has been largely overlooked by existing therapies: progression independent of relapse activity (PIRA).
Recent scientific literature highlights that MS disability can worsen even in the absence of clinical relapses, a phenomenon known as PIRA. This progression is believed to be driven by chronic active, or “smoldering,” lesions and compartmentalized inflammation within the central nervous system. These mechanisms may contribute to ongoing tissue damage that is not adequately addressed by treatments that primarily target peripheral immune activity.
Lucid-MS takes a different approach. Instead of broadly suppressing the immune system, it targets myelin degradation—the underlying cause of MS-related disability. By preserving myelin, the protective sheath around nerve fibers, Lucid-MS aims to support functional recovery and potentially halt or slow disease progression. This mechanism of action sets it apart from conventional MS therapies, which focus on reducing immune-mediated attacks but may not fully address the smoldering inflammation within the brain and spinal cord.
Quantum BioPharma has made significant strides in advancing Lucid-MS through clinical development. The company has collaborated with Massachusetts General Hospital on PET imaging techniques designed to assess myelin integrity in vivo. This imaging capability could serve as a valuable biomarker for monitoring treatment efficacy and disease progression in future trials.
Recently, Quantum BioPharma received clearance to begin a Phase 2 trial of Lucid-MS. This follows Phase 1 studies that reported a favorable safety profile in healthy volunteers, a crucial milestone for any investigational therapy. The initiation of Phase 2 trials represents a critical step in evaluating the drug’s efficacy in patients with MS.
The potential impact of this research is significant. If Lucid-MS proves effective, it could offer a new therapeutic option for the millions of people living with MS worldwide. By addressing the neurodegenerative component of the disease, it may help mitigate disability accumulation even in patients who do not experience frequent relapses. This could lead to improved long-term outcomes and quality of life for MS patients.
Quantum BioPharma is a biopharmaceutical company dedicated to building a portfolio of innovative assets for challenging neurodegenerative, metabolic, and alcohol misuse disorders. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., the company is focused on the research and development of Lucid-MS, a patented new chemical entity that has shown the ability to prevent and reverse myelin degradation in preclinical models.
In addition to its MS program, Quantum BioPharma has developed UNBUZZD(TM), a product for alcohol misuse, and has spun out its OTC version to Unbuzzd Wellness Inc. (UWI). Quantum retains a 19.48% ownership stake in UWI and is entitled to royalty payments of 7% of sales from UNBUZZD(TM) until payments total $250 million, after which the royalty drops to 3% in perpetuity. The company also retains full rights to develop similar products for pharmaceutical and medical uses.
The latest news and updates relating to Quantum BioPharma are available in the company’s newsroom at https://ibn.fm/QNTM.
